Bristol Myers Squibb Company (BMY) vs Pfizer Inc. (PFE)
- Bristol Myers Squibb Company BMY 59.71 −1.42%
- Pfizer Inc. PFE 29.58 +0.48%
Bristol Myers Squibb Company and Pfizer Inc. are both Drug Manufacturers General companies. Pfizer Inc. is the larger, with a market value of $167.8B against $123.7B — 1.4× the size. Bristol Myers Squibb Company trades at the lower P/E: 13.2× against 38.9×. Bristol Myers Squibb Company grew revenue faster over the last twelve months: 3.11% against −0.21%. Bristol Myers Squibb Company has the higher net margin (18.9% vs 6.80%) and the higher return on invested capital (13.7% vs 6.30%). Both pay a dividend; Pfizer Inc. yields more (5.81% vs 4.22%). Across the 23 metrics below, Bristol Myers Squibb Company leads on 17 and Pfizer Inc. on 6.
Valuation
Profitability
| Metric | BMY | PFE | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 70.16% | 73.18% | 72.77% |
| Operating margin | 24.22% | 21.70% | 18.77% |
| Net margin | 18.87% | 6.80% | 8.27% |
| Free cash flow margin | 23.26% | 17.25% | 17.18% |
| Return on equity | 46.63% | 4.97% | 5.87% |
| Return on assets | 10.18% | 2.13% | 2.57% |
| Return on invested capital | 13.69% | 6.30% | 6.11% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack